Rachel Yesharim joins the company’s executive team to help build AposIQ® – a new business unit applying cutting edge technology and data science to inform gait-related treatments.
AposHealth®, a global leader in the identification and treatment of gait-related conditions, today announced that Rachel Yesharim has joined the executive team as Chief Technology Officer. Rachel brings to the team extensive experience building AI-powered software products as well as a new energy to propel AposHealth® as it continues to grow the market for treating gait-related conditions. Rachel will be heavily involved in building AposIQ®, which combines sensor technology, AI–driven video gait assessment, clinician assessment, patient reported outcome measures, data science, and over a decade of experience in gait modification, to determine the optimal way to adjust patients’ gaits over time.
Prior to AposHealth®, Rachel was Vice President of Product at Medial EarlySign where she led EarlySign’s product vision to deliver novel solutions, while paving the way for the implementation of AI in health care. Rachel worked in collaboration with leading healthcare organizations in the US to design and deliver algorithmic insights and empower medical professionals with proactive, predictive, and personalized care capabilities. Rachel began her career at Intel® where she held various leading roles over 10 years, including product management roles within Intel’s Advanced Analytics unit. Rachel holds a BSc in Computer Science with a specialization in Bioinformatics.
“We are thrilled to welcome Rachel to the executive team,” said Cliff Bleustein, MD, MBA, President and CEO of AposHealth®. “Rachel’s unique background and experience will accelerate the development of new technologies to better understand the impact of gait on health and give people the power to move.”
About AposHealth®
AposHealth® is a global leader in the identification and treatment of gait-related conditions with global headquarters in Tel Aviv, IL, with US and UK headquarters in New York and London, respectively.
AposHealth®’s foot-worn device is FDA-cleared for treating knee osteoarthritis, to help temporarily reduce knee pain and improve lower extremity function during activities of daily living. It is also a non-FDA cleared wellness device which can help patients live well with other gait-related conditions such as chronic low back and hip pain.
By improving body mechanics and muscular coordination, AposHealth® has shown in clinical research that patients can achieve significant pain relief as well as an improvement in their daily physical function.
Connect with AposHealth® on Facebook, Twitter, YouTube, and LinkedIn.
